



Cytogenetic Abnormalities

Chromosomal, FISH and
Microarray-Based Clinical Reporting

Susan Mahler Zneimer

WILEY Blackwell

Cytogenetic Abnormalities

Cytogenetic Abnormalities

Chromosomal, FISH and Microarray-Based Clinical Reporting

Susan Mahler Zneimer, Ph.D., FACMGG

CEO and Scientific Director, MOSYS Consulting

Adjunct Professor, Moorpark College, Moorpark, California

WILEY Blackwell

This edition first published 2014 © 2014 by John Wiley & Sons, Inc.

Registered Office

John Wiley & Sons, Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

Editorial Offices

9600 Garsington Road, Oxford, OX4 2DQ, UK

The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

111 River Street, Hoboken, NJ 07030–5774, USA

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/wiley-blackwell.

The right of the author to be identified as the author of this work has been asserted in accordance with the UK Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book.

Limit of Liability/Disclaimer of Warranty: While the publisher and author(s) have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. It is sold on the understanding that the publisher is not engaged in rendering professional services and neither the publisher nor the author shall be liable for damages arising herefrom. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

Library of Congress Cataloging-in-Publication Data

Zneimer, Susan Mahler, author.

Cytogenetic abnormalities : chromosomal, FISH, and microarray-based clinical reporting /

Susan Mahler Zneimer.

p. ; cm.

Includes bibliographical references and index.

ISBN 978-1-118-91249-2 (paperback)

I. Title.

[DNLM: 1. Chromosome Aberrations. 2. Cytogenetic Analysis. 3. In Situ Hybridization, Fluorescence. 4. Microarray Analysis. 5. Neoplasms—pathology. 6. Terminology as Topic. QS 677]

QH600

572.8'7—dc23

2014018423

A catalogue record for this book is available from the British Library.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

Set in 10/12pt Adobe Garamond by SPi Publisher Services, Pondicherry, India

Dedication

To my husband, Martin Chetlen, for his guidance, love and support, without which this book neither could nor would ever have been written.

And to my parents, Nadine and Joel, who raised me to think, and to imagine all the possibilities. May their memory be forever a blessing.

To all three, I raise my glass and say... thank you!

Contents

Preface	xiv
Acknowledgments	xv
About the companion website	xvi

Introduction	1
---------------------	----------

Part 1: Constitutional Analyses	5
--	----------

Section 1: Chromosome Analysis	7
---------------------------------------	----------

1 Components of a standard cytogenetics report, normal results and culture failures	9
1.1 Components of a standard cytogenetics report	9
1.2 Prenatal normal results	17
1.3 Neonatal normal results	22
1.4 Normal variants in the population	23
1.5 Disclaimers and recommendations	29
1.6 Culture failures	30
1.7 Contamination	32
2 Mosaicism	35
2.1 Normal results with 30–50 cells examined	37
2.2 Normal and abnormal cell lines	37
2.3 Two or more abnormal cell lines	39
3 Autosomal trisomies – prenatal and livebirths	41
3.1 Introduction	41
3.2 Trisomy 21 – Down syndrome	42
3.3 Mosaic trisomy 21 – mosaic Down syndrome	43
3.4 Trisomy 13 – Patau syndrome	44
3.5 Trisomy 18 – Edwards syndrome	45
3.6 Trisomy 8 – mosaic	46
3.7 Trisomy 9 – mosaic	47
3.8 Trisomy 20 – mosaic, prenatal	47
3.9 Trisomy 22 – mosaic, prenatal	48
4 Translocations	51
4.1 Reciprocal (balanced) translocations	51
4.2 Robertsonian translocations	58

5	Inversions and recombinant chromosomes	67
5.1	Risks of spontaneous abortions and liveborn abnormal offspring	67
5.2	Pericentric inversions and their recombinants	67
5.3	Paracentric inversions and their recombinants	71
6	Visible deletions, duplications and insertions	75
6.1	Definitions	75
6.2	Visible duplications	79
6.3	Balanced insertions	80
7	Unidentifiable marker chromosomes, derivative chromosomes, chromosomes with additional material and rings	85
7.1	Marker chromosomes	85
7.2	Derivative chromosomes	87
7.3	Chromosomes with additional material	90
7.4	Ring chromosomes	91
7.5	Homogenously staining regions	94
8	Isochromosomes, dicentric chromosomes and pseudodicentric chromosomes	97
8.1	Isochromosomes/dicentric chromosomes	97
8.2	Pseudodicentric chromosomes	104
9	Composite karyotypes and other complex rearrangements	107
9.1	Composite karyotypes	107
9.2	Complex rearrangements	109
10	Sex chromosome abnormalities	115
10.1	X chromosome aneuploidies – female phenotypes	115
10.2	X and Y chromosome aneuploidies – male phenotypes	120
10.3	X chromosome structural abnormalities	122
10.4	Y chromosome structural abnormalities	128
10.5	46,XX males and 46,XY females	132
10.6	X chromosome translocations	135
11	Fetal demises/spontaneous abortions	143
11.1	Aneuploid rate	143
11.2	Confined placental mosaicism	144
11.3	Hydatidiform moles	145
11.4	Monosomy X in a fetus	146
11.5	Trisomies in a fetus	146
11.6	Double trisomy	149
11.7	Triploidy	150
11.8	Tetraploidy	151
12	Uniparental disomy	155
12.1	Uniparental disomy of chromosome 14	157
12.2	Uniparental disomy of chromosome 15	158
12.3	Uniparental disomy of chromosome 11p15	159

Section 2: Fluorescence <i>In Situ</i> Hybridization (FISH) Analysis	161
13 Metaphase analysis	163
13.1 Introduction	163
13.2 Reporting normal results	164
13.3 Common disclaimers	166
13.4 Microdeletions	167
13.5 Microduplications	190
13.6 Fluorescence <i>in situ</i> hybridization for chromosome identification	198
13.7 Subtelomere fluorescence <i>in situ</i> hybridization analysis	200
14 Interphase analysis	205
14.1 Introduction	205
14.2 Example report of interphase analysis	206
14.3 Common disclaimers	207
14.4 Reporting normal results	208
14.5 Abnormal prenatal/neonatal results	211
14.6 Abnormal product of conception FISH abnormalities	218
14.7 Molar pregnancies	222
14.8 Preimplantation genetic diagnosis	222
15 Integrated chromosome and FISH analyses	231
15.1 ISCN rules and reporting normal results by chromosomes and FISH	232
15.2 ISCN rules and reporting abnormal chromosomes and FISH	233
15.3 ISCN rules and reporting of chromosomes and subtelomere FISH	237
Section 3: Chromosomal Microarray Analysis (CMA)	243
16 Bacterial artificial chromosome, oligoarray and single nucleotide polymorphism array methodologies for analysis	245
16.1 Introduction	245
16.2 Clinical utility of chromosomal microarray analysis	250
16.3 Guidelines for classification states	251
16.4 ISCN rules and reporting of normal results	252
16.5 Comments, disclaimers and recommendations	253
17 Microarray abnormal results	257
17.1 Reporting of abnormal results	257
17.2 Loss or gain of a single chromosome	258
17.3 Loss or gain of a whole chromosome complement	262
17.4 Microdeletions	263
17.5 Microduplications	265
17.6 Derivative chromosomes	267
17.7 Variants of unknown significance	269
17.8 Uniparental disomy/loss of heterozygosity/regions of homozygosity	269

17.9	Mosaicism	271
17.10	Common comments in abnormal reports	273
17.11	Microarrays with concurrent FISH studies and/or chromosome studies	274
17.12	Microarrays with concurrent parental studies	274
17.13	Preimplantation genetic diagnosis testing	275
17.14	Non-invasive prenatal testing	276
18	Pathogenic chromosomal microarray copy number changes by chromosome order	285
18.1	Chromosome 1	285
18.2	Chromosome 2	287
18.3	Chromosome 3	289
18.4	Chromosome 4	290
18.5	Chromosome 5	291
18.6	Chromosome 7	292
18.7	Chromosome 8	293
18.8	Chromosome 14	294
18.9	Chromosome 15	294
18.10	Chromosome 16	296
18.11	Chromosome 17	298
18.12	Chromosome 19	301
18.13	Chromosome 22	302
18.14	Chromosome X	306
19	Integrated reports with cytogenetics, FISH and microarrays	315
19.1	Reporting of a deletion	315
19.2	Reporting of a supernumerary chromosome	316
19.3	Reporting of an unbalanced translocation – deletion/duplication	318
19.4	Reporting of multiple abnormal cell lines	322
Part 2:	Acquired Abnormalities in Hematological and Tumor Malignancies	325
Section 1:	Chromosome Analysis	327
20	Introduction	329
20.1	Description of World Health Organization classification for hematological malignancies	332
20.2	Description of different tumor types with significant cytogenetic abnormalities	332
20.3	Set-up and analysis of specific cultures for optimal results	333
20.4	Nomenclature rules for normal and simple abnormal results	336
20.5	Common report comments for hematological malignancies	338
21	Results with constitutional or other non-neoplastic abnormalities	347
21.1	Possible constitutional abnormalities observed	347
21.2	Age-related abnormalities	349
21.3	Non-clonal aberrations	351
21.4	No growth and poor growth	354

22 Cytogenetic abnormalities in myeloid disorders	357
22.1 Introduction to myeloid disorders	357
22.2 Individual myeloid abnormalities by chromosome order	360
23 Cytogenetic abnormalities in lymphoid disorders	395
23.1 Introduction to lymphoid disorders	395
23.2 Hyperdiploidy and hypodiploidy	396
23.3 Individual lymphoid abnormalities by chromosome order	398
24 Common biphenotypic abnormalities and secondary changes	423
24.1 Translocation (4;11)(q21;q23)	423
24.2 Del(9q)	424
24.3 Translocation (11;19)(q23;p13.3)	424
24.4 Del(12)(p11.2p13)	425
24.5 Trisomy 15	425
24.6 i(17q)	426
25 Reporting complex abnormalities and multiple cell lines	429
25.1 Stemline and sideline abnormalities	430
25.2 Unrelated abnormal clones	434
25.3 Composite karyotypes	435
25.4 Double minute chromosomes	436
25.5 Modal ploidy numbers	438
25.6 Multiple abnormal cell lines indicative of clonal evolution	440
26 Breakage disorders	445
26.1 Ataxia telangiectasia	445
26.2 Bloom syndrome	446
26.3 Fanconi anemia	447
26.4 Nijmegen syndrome	448
27 Cytogenetic abnormalities in solid tumors	451
27.1 Clear cell sarcoma	451
27.2 Chondrosarcoma	452
27.3 Ewing sarcoma	453
27.4 Liposarcoma	453
27.5 Neuroblastoma	454
27.6 Rhabdomyosarcoma	455
27.7 Synovial sarcoma	456
27.8 Wilms tumor	456
Section 2: Fluorescence <i>In Situ</i> Hybridization (FISH) Analysis	459
28 Introduction to FISH analysis for hematological disorders and solid tumors	461
28.1 General results	462
28.2 Bone marrow transplantation results	468

29 Recurrent FISH abnormalities in myeloid disorders	471
29.1 Individual abnormalities in myeloid disorders by chromosome order	471
29.2 Biphenotypic and therapy-related abnormalities	491
29.3 Panels of probes	492
30 Recurrent FISH abnormalities in lymphoid disorders	499
30.1 Individual abnormalities in lymphoid disorders by chromosome order	499
30.2 Panels of probes	520
31 Integrated reports with cytogenetics and FISH in hematological malignancies	531
31.1 Translocation (9;22) with BCR/ABL1 FISH analysis	531
31.2 Monosomy 7 with a marker chromosome and chromosome 7 FISH analysis	532
31.3 Complex abnormalities with the MDS FISH panel	532
31.4 Complex abnormalities with ALL FISH panel	533
31.5 Complex abnormalities with MM FISH panel	535
31.6 Complex abnormalities with AML FISH panel	536
31.7 Complex abnormalities with AML FISH panel in therapy-related disease	537
32 Recurrent FISH abnormalities in solid tumors using paraffin-embedded tissue	541
32.1 Ewing sarcoma	544
32.2 Liposarcoma	545
32.3 Neuroblastoma	546
32.4 Non-small cell lung cancer	547
32.5 Oligodendroglioma	552
32.6 Rhabdomyosarcoma	554
32.7 Synovial sarcoma	554
33 Breast cancer – HER2 FISH analysis	559
33.1 Common report comments	560
33.2 Example HER2 reports	561
33.3 Genetic heterogeneity	563
34 Bladder cancer FISH analysis	569
34.1 Common report comments	570
34.2 Example reports	570
Section 3: Chromosomal Microarray Analysis (CMA)	577
35 Chromosomal microarray analysis for hematological disorders	579
35.1 Introduction	579
35.2 Categories of abnormalities	580
35.3 Complex abnormalities throughout the genome, chromothripsis and homozygosity	581
35.4 Normal results and disclaimers	582
35.5 Example abnormal results in hematological malignancies	583

36 Chromosomal microarrays for tumors	595
36.1 Introduction and disclaimers	595
36.2 Breast cancer	596
36.3 Lung cancer	604
36.4 Colon cancer	606
36.5 Prostate cancer	607
36.6 Unspecified tumor present	607
37 Integrated reports with chromosomes, FISH and microarrays	611
37.1 Homozygous deletion of 9p21 identified by FISH and CMA	611
37.2 Identifying marker chromosomes by chromosome analysis, FISH and CMA	612
37.3 Unbalanced translocation identification by chromosomes, FISH and CMA	614
Appendix 1: Example assay-specific reagent (ASR) FISH validation plan for constitutional disorders and hematological malignancies on fresh tissue	617
Glossary	623
Index	641

Preface

Numerous books and an untold number of publications in the scientific literature describe various chromosome abnormalities, both common and rare. One can search for any chromosome abnormality in a book index or an online scientific database and find every possible chromosome change that has been identified. Most of these abnormalities are reported, rightly so, in order to make a correlation with a clinical phenotype, diagnosis or prognosis of a disease. In other words, the emphasis has always been on directly correlating chromosome abnormalities with disease.

However, to date, little emphasis has been placed on standardizing how to designate chromosome abnormalities with their nomenclature and the related interpretation of these results with patient diagnoses. This book attempts to address the lack of standardization for writing the nomenclature of chromosome abnormalities and interpretive comments regarding those abnormalities. With over 250 cytogenetic laboratories in the United States alone, and maybe 500 laboratories worldwide, it is indeed time to develop more established guidelines for writing and interpreting cytogenetic, fluorescence *in situ* hybridization (FISH) and microarray test results.

The International System for Human Cytogenetic Nomenclature (ISCN) is the only resource (albeit a great one) to use in order to designate clear nomenclature in writing test results. Even so, if one is to compare a cytogenetic result from 10 different laboratories in the designation of a marker chromosome, for example, there could easily be five different ways to either write the ISCN nomenclature or interpret the result.

This book will be useful to cytogeneticists who write test results, to other geneticists, physicians, allied professionals and scientists who need to read these reports or use them in their clinical and/or research endeavors, and to those medical and human genetic students who are required to understand cytogenetic test results.

In this book, for each normal and abnormal cytogenetic result, the ISCN nomenclature and an interpretive comment with related recommendations are given. These abnormalities are divided among constitutional disorders and acquired malignancies, and are described by their genetic composition, genetic nomenclature and associated clinical features. Each chapter also contains a bibliography from which the information was obtained as well as pertinent research articles, databases and/or online web addresses for the reader's reference.

This book attempts to discuss as many genetic and malignant diseases as possible that have a known and prominent underlying genetic defect; however, it is not possible to list all the cytogenetic abnormalities in one manuscript. Readers who wish to see other abnormalities not included in the manuscript are encouraged to contact the author for reference in a future edition of the book.

Acknowledgments

I wish to thank those who have graciously read my manuscript for content and coherence. Special thanks go to Nancy Wold and Martin Chetlen for all their assistance and guidance throughout the duration of this product. Nancy Wold, in particular, has been a great help in making this manuscript readable and understandable. She has played a large role in seeing this project come to fruition through her encouragement and support. My thanks are inadequate for all her endeavors.

I would also like to thank Robert Winning for all his help with formatting the images.

I would also like to thank the many cytogenetic directors and laboratory staff who have helped me with their wisdom, experience and advice. All of these people and their laboratories have provided me with invaluable information, including many of the images in the book.

My deep appreciation goes to the directors and staff of the following laboratories.

- ARUP Laboratories: Dr Sarah South, Lynda Kerby, Tamara Davis and Bonnie Issa.
- Ascend Genomics (formerly PathCentral): Dr Mansoor Mohamed and Dr Shelly Gunn.
- City of Hope: Dr Joyce Murata-Collins, Popsie Gaytan, David Eve, Gina Alvarez, Maria Cruz.
- CombiMatrix: Dr Karine Hovanes, Dr Richard Hockett Jr.
- Kaiser Permanente Laboratories: Dr Lauren Jenkins, Dr Mehdi Jahmedhor, Dr Xu Li, Lloyd Maxwell, Michael Tiffert, Virginia Nottoli, Grace Santiago.
- LabCorp of America: Dr Peter Papenhausen, Dr James Tepperberg, Dr William Kearns, Dr Bing Huang, Martin Sasaki, Ati Girgin, Monika Skapino, Sharlene Anderson, Kristen Trujillo, AnnMarie Bell, Kenny Xi, Rosa Thompson and Jose Navarro.
- Natera: Dr Zackary Demko, Dr Matt Hill, Dr Megan Hall and Sallie McAdoo.

It is such a pleasure to have great colleagues with whom to work. I am forever indebted to all of you for your assistance in the completion of this manuscript.

I would also like to thank my colleagues, Dr Lauren Jenkins and Dr Paula Berry, for their long-term friendship, treasured advice and encouragement in completing this manuscript.

Lastly, I would like to thank my editor, Justin Jeffryes and all those at Wiley Publishing, for their encouragement and help in initiating and completing this enormous project.

I have spent most of the day putting in a comma and the rest of the day taking it out.

Oscar Wilde

About the companion website

This book is accompanied by a companion website:

www.wiley.com/go/zneimer/cytogenetic

The website includes:

- PDFs of all Example Report Boxes from the book for downloading. The Example Reports are the most important downloads that are needed for the book
- Powerpoints of all figures from the book for downloading
- PDFs of all tables from the book for downloading.

Introduction

Genetic testing is complex, and it is often difficult to understand the meaning of its results. One part of genetic testing is cytogenetic testing, often called chromosome analysis, which uses whole cells that are grown in culture in the laboratory to isolate DNA and identify differences of the chromosomes that would yield a genetic abnormality and lead to a genetic disorder or cancer. Cytogenetic analysis requires extensive manipulation of cells taken from an individual's body to isolate and analyze the chromosomes microscopically for the identification of chromosome aberrations. The complexity of this testing continues with writing a comprehensive and cohesive laboratory report that contains the correct information and correct nomenclature, and is understandable by the professional community that is conveying these results to patients. All too often, without assistance from genetic counselors, the professional receiving cytogenetic results from the genetics laboratory does not understand the nomenclature or the interpretive comments that explain a cytogenetics abnormality. These results are then not appropriately conveyed to the patient, widening the divide between medical science and the general population.

This book begins with an overview of genetics in general, cytogenetics in particular, and how its significance pertains to the general population. The discussion continues in subsequent chapters, in which specific cytogenetic abnormalities are discussed, and includes how cytogenetic reports are written for each abnormality, and how professionals and individuals with these disorders should interpret cytogenetic results.

Overview of cytogenetic testing in the laboratory

Cytogenetic testing is the study of chromosomes and their genetic composition, which is studied at different genetic levels. The “Gestalt” view of cytogenetics is the largest overview of chromosomes in which the banding level is important in identifying gross versus subtle, but visible, genetic changes. This level is generally referred to as standard or conventional cytogenetics. Conventional cytogenetics allows for the identification of large DNA changes that are visible on a chromosome, at least 1 million base pairs, whether the genetic change is a balanced or unbalanced abnormality. It is still the method of choice for many types of indications for genetic testing, such as cancer diagnosis and prognosis,

history of spontaneous abortions, newborn dysmorphology, prenatal diagnosis and endocrinology disorders. There are limitations to conventional cytogenetics, one of which is the inability to visualize small abnormalities under a microscope, <1–5 million base pairs, eliminating the possibility of identifying submicroscopic genetic abnormalities. This limitation led to the development of new methodologies, including fluorescence *in situ* hybridization and microarray techniques, which enable the identification of smaller genetic changes and do not depend on the level of chromosome banding and morphology.

The next level of chromosome analysis is the level at which DNA probes can be used to identify regions of a chromosome using *in situ* hybridization (ISH). Although the first ISH analysis was done using radioactive tritium as a DNA probe, now the conventional approach uses fluorescent dyes attached to a small segment of DNA, hundreds to thousands of DNA base pairs long, that is specific to chromosomal regions of interest. This fluorescence *in situ* hybridization (FISH) is very useful in identifying DNA change on the chromosome that is specific to a disease region, a locus-specific region or a part of a chromosome that is used for chromosomal identification, such as a centromere, subtelomere or whole chromosome paint probe. FISH is very useful in identifying deletions, duplications and rearrangements of small disease regions where DNA probes can be made, or for chromosomal identification, when the presence of a chromosome is unidentifiable by standard chromosome analysis. FISH analysis also has its limitations, due to the small range of DNA size that supports a probe for hybridization. This range is generally from DNA segments from 1000 to 200,000 base pairs long. Another limitation of FISH is the need to know which region of a chromosome with which to probe. This is a targeted DNA test of the genome and only segments of interest are utilized in this methodology. Only with whole chromosome paint probes will the total genome be visible with the FISH methodology.

The next level of chromosome analysis is microarray technology. This method allows for a whole genome analysis at the molecular level in which small segments of DNA probes (oligo DNA probes) down to single base pair analyses (single nucleotide polymorphisms, SNPs) are used to identify all the segments of a genome for DNA imbalances in individuals. This methodology has become quite prevalent in all aspects of cytogenetic analysis, since large and small imbalances, including unbalanced rearrangements, duplications and deletions of any size, can be identified in an individual. Therefore, this type of analysis is replacing many aspects of the standard chromosome and FISH analyses, especially when specific indications for cytogenetic testing are known to be submicroscopic, and no clear disease state is in the differential diagnosis.

Table 1 Levels of DNA resolution from standard chromosome analysis by specimen type

Specimen type	Average band level	Average number of genes per band	Average number of base pairs per band	Band width in Mb
Bone marrow	350	100	9×10^6	9
Prenatal (AF and CVS)	450	75	7×10^6	7
Routine blood	550	60	6×10^6	6
High-resolution blood	800	45	4×10^6	4

AF, amniotic fluid; CVS, chorionic villus sampling.

Table 2 Abnormality detection by methodology

Abnormality	G-band	FISH (targeted sites)	Chromosome microarray analysis (CMA)
Whole chromosome imbalance (aneuploidy)	+	+	+
Balanced rearrangement (reciprocal translocations, inversions)	+	+	-
Deletions, duplications >10 Mb	+	+	+
Deletions, duplications <5~10 Mb (submicroscopic)	-	+	+
Mosaicism, if present at these levels	>20%	>5%	>20%
Marker (unidentifiable) chromosomes (non-mosaic)	+	+	+
Triploidy	+	+	+

FISH, fluorescence *in situ* hybridization.

The most significant use of microarray technology is for non-specific disorders, such as indications of autism spectrum disorders, mental impairment, developmental delay and brain or other organ dysfunction. It has also become prevalent for prenatal diagnosis and cancer disorders when many non-random, recurrent genetic changes are possible or, for example, in leukemias where many cytogenetic changes are known to be the underlying genetic change causing disease. A single microarray analysis is a good method to identify any of the possible abnormalities of gain or loss of genetic material known to be involved in specific diseases. This is in contrast to the many FISH probes that may be needed to test for a single disease or chromosome analysis, which is difficult to perform on neoplastic cells.

Microarray analysis, however, also has some limitations, including that it is most effective for identifying unbalanced rearrangements, whereas balanced rearrangements are not detectable (though this will probably be developed for clinical use in the near future). Microarray analysis is also too new to be the standard of care for most indications for genetic testing. However, ongoing development of this methodology will most likely make this type of testing more prevalent in the future.

See Tables 1 and 2 for a summary of the detection of chromosome abnormalities at each level and methodology employed.

Laboratory procedures for each type of methodology can be found in other sources, which are listed at the end of this chapter.

Genetic testing in most countries is generally governed by at least one agency. Some information regarding governmental and other regulatory agency requirements is provided but regulations vary depending on the state and country or residence of the laboratory or patient. Each government and agency has specific guidelines or laws that guide the laboratory for ethical, quality and monetary aspects. Other regulations in the United States include statements regarding whether a test is FDA approved or is an assay specific reagent (ASR) or for research use only (RUO). For the needed statement on reports, see Part 1, Section 2, where this is applicable.

Other rules and regulations will be discussed throughout the book when applicable.

Bibliography

- Gardner RJM, Sutherland GR. *Chromosome Abnormalities and Genetic Counseling*. Oxford Monographs on Medical Genetics. Oxford University Press, Oxford, 2003.
- Gersen S, Keagle M (eds). *Principles of Clinical Cytogenetics*. Humana Press, Totowa, New Jersey, 1999.
- Grewal SI, Jia S. Heterochromatin revisited. *Nat Rev Genet* 2007; 8: 35–46.
- McKusick VA. Mendelian Inheritance in Man and its online version, OMIM. *Am J Hum Genet* 2007; 80: 588–604.
- Rooney DE, Czepulkowski BH. *Human Cytogenetics. A Practical Approach*. Oxford University Press, New York, 1992.
- Shaffer LG, McGowan-Jordan J, Schmid M (eds). *ISCN 2013: An International System for Human Cytogenetic Nomenclature*. Karger Publishers, Unionville, CT, 2013.
- Tobias E, Connor M, Ferguson Smith M. *Essential Medical Genetics*, 6th edn. Wiley-Blackwell, Oxford, 2011.
- Tolmie JL, MacFadyen U. Down syndrome and other autosomal trisomies. In: Rimoin D, O'Connor J, Pyeritz R, Korf B (eds) *Emery and Rimoin's Principles and Practice of Medical Genetics*, 5th edn. Churchill Livingstone, Edinburgh, 2006, pp.1015–1037.

Part 1

Constitutional

Analyses

Section 1

Chromosome

Analysis

CHAPTER 1

Components of a standard cytogenetics report, normal results and culture failures

1.1 Components of a standard cytogenetics report

All cytogenetic reports should have specific information which helps to standardize that each laboratory is performing a minimum standard of competency and accuracy of results. Clinical laboratory improvement amendments (CLIA), College of American Pathologists (CAP) and various US states have placed requirements on each report. The information below is required for CLIA, CAP, NY State and CA State for regulatory compliance.

- Specimen type
- Indication for testing
- Number of cells counted
- Number of cells analyzed
- Number of cells karyotyped
- Banding technique
- ISCN nomenclature
- Interpretation

1.1.1 Specimen type

Specimen type refers to the source of tissue that is being analyzed for cytogenetic testing. The most common specimen types are:

- amniotic fluid and chorionic villus sampling (CVS) for prenatal studies
- peripheral blood for studies of liveborn individuals
- fetal tissue for products of conception (fetal demise) studies
- bone marrow, bone core or peripheral blood for leukemias
- bone marrow or lymph nodes for lymphomas
- muscle or skin biopsies for possible mosaic studies
- tumor biopsies for acquired or inherited malignancies.

1.1.2 Indication for testing

Obtaining relevant clinical information about the patient is important in order to correlate cytogenetic results with the diagnosis. It sometimes becomes necessary for the laboratory to determine the appropriate set-up conditions of the specimen and the types of testing to perform, due to the various possibilities that exist. Therefore, in order for the laboratory to know what specific testing to perform, it needs all relevant patient information. Without the necessary patient and family clinical information, it may become a guessing game for the laboratory on the correct processing step to take. This is especially significant when it applies to cancer cytogenetics. Since certain cancer cells, including acute leukemias and myeloid disorders, divide continuously and do not require a B-cell or T-cell mitogen stimulant for cells to go through mitosis, the cultures that are initiated should be unstimulated 24-hour and 48-hour cultures. This is in contrast to chronic leukemias and other lymphoproliferative disorders, which do better with a B- or T-cell mitogen (e.g. IL4, TPA) to stimulate the cells to divide to have enough metaphases for analysis and which contain the abnormal cell type rather than normal lymphocytes. Also, knowing if acute lymphoblastic leukemia (ALL) is an indication for a patient will require only direct, overnight or 24-hour unstimulated cultures for analysis. Otherwise, there will be an overgrowth of normal cells dividing by the second day, and the abnormal lymphoblasts that are indicative of ALL will die off and not be present for analysis.

Culture initiation or set-up is also specific for the tumor type in question. No one culture medium is sufficient for all tumor types and so the culture medium should be specifically tailored for the proper growth of the abnormal tumor cells. For a guide on cancer cell culture media and growth factors for neoplastic cell growth, see the bibliography for detailed information.

1.1.3 Number of cells counted and analyzed

Counted cells refer to identifying a single cell and counting the number of chromosomes present plus identifying the sex chromosomes of that cell. Analyzed cells refer to identifying each chromosome homolog, band for band, to determine if any abnormalities exist within any of the chromosomes present.

Colonies refer to amniotic fluid cells that are cultured *in situ* on a small culture vessel, such as a coverslip. Colonies originate from single amniotic fluid cells that will grow and divide near each other in a colony, visibly separated from other originating amniotic fluid colonies. This type of culture allows for a greater distinction of progenitor cells in analysis versus allowing cells to congregate, grow and divide without spatial distinction, in which there is no knowledge of which cells are progenitor cells and which are the result of cell division and clones of progenitor cells. Without colonies, the cells in culture may be growing and dividing from only a very few hardy cells, and could possibly result in only a small number of original cells being analyzed, excluding possible mosaicism at a lower level.

The standard number of cells to be counted and analyzed depends on the specimen type. See Table 1.1 for a guide to the most common guidelines for cells counted and analyzed.

	Postnatal peripheral blood	Prenatal amniotic fluid	Prenatal chorionic villous sampling	Neoplastic bone marrow and blood	Fetal demise and liveborn tissues	Neoplastic tumors	Mosaic studies
Cells counted	20	15 colonies or 20 cells	20	20	20	20–30	30–50
Cells analyzed	5	5 colonies or 5 cells	5	20	5	20–30	5

1.1.4 Number of cells karyotyped

The number of cells to be karyotyped is generally two per cell line. Exceptions to this rule include karyotyping only one cell of sideline clones in a neoplastic study, which will be discussed in greater detail in the cancer section of the book. More than two cells may be karyotyped if an abnormality is subtle and requires more than two cells to clarify the abnormality present.

1.1.5 Banding techniques

The standard banding techniques include those that clearly distinguish the significant bands identified by the International System for Human Cytogenetic Nomenclature (ISCN). The most common banding techniques which show the best banding patterns include G-banding, R-banding and Q-banding. Each technique uses different staining procedures to visualize the differential staining of cytosine/guanine (CG)-rich and adenosine/thymine (AT)-rich DNA. In each staining procedure, the bands observed are the same, but are visualized by AT with dark bands and CG with light bands or vice versa.

Other banding techniques are used to enhance specific regions of the chromosome, such as the centromere with C-banding, satellite regions of acrocentric chromosomes with nuclear organizer region (NOR) staining or telomeric regions with T-banding.

For a comprehensive discussion of banding techniques, refer to the bibliography at the end of the chapter.

1.1.6 Band levels

The banding level refers to an estimated total number of black, gray and white bands throughout the genome as it would appear in an ideogram of each chromosome. In the ISCN 2013 edition, on pages 16–31, ideograms of the chromosomes are described by band levels. There are a few reports in the literature of standardizing approaches to count the total number of bands in a karyotype. One approach is to count bands including the telomere, centromere and all the dark and light bands on chromosome 10. Table 1.2 details the correlation between the number of bands with the band level, using chromosome 10 as a reference.

Another approach for estimating band level is to count segments of specific chromosomes. For two different approaches, see a summary of these band estimations in Tables 1.3 and 1.4. Examples of cells with their corresponding karyotypes of each band level are depicted in Figure 1.1.

In a cytogenetics report, recording band level is generally a requirement. There is some debate on whether the highest band level observed in the best cell should be recorded in the report, or whether the band level of the best karyotype should be reported, or an average of the cells or karyotypes. Many laboratories record the best band level seen in a karyotype, which is easily documented for regulatory purposes and which may be corroborated if that karyotypic image is placed in the report itself.

Typically, the band level of a normal prenatal specimen of amniotic fluid and chorionic villus sampling is approximately 450 bands. For peripheral blood on liveborns, the typical band level is 500–550 bands. Hematological malignancies and solid tumors typically have fewer bands, generally in the range of 300–400 bands, reflecting the difficulty in analyzing dividing cells from abnormal cell types in malignancies.

When performing a high-resolution study, in which the minimum band level is 550–650 bands, a comment in the interpretation may be useful in order for the reader to know at what level chromosome analysis was achieved. It is also useful to report when the banding level did not reach the minimum requirement established by the laboratory or regulatory agency.

Table 1.2 Band level by counting the bands on chromosome 10 (adapted from Welborn and Welborn 1993)

Number of bands on chromosome 10	Estimated band level
12	375
13–14	400
15–16	425
17–18	450
19–21	475
22–23	500
24–25	525
26–28	550
29–30	600
31–32	650
33–34	700
35–36	750
37–38	800
39–40	850

Table 1.3a Tabulated band resolution of chromosomal segments (adapted from Josifek et al. 1991)

Chromosome region	Total bands counted for each band level		
	Band level 350–400	Band level 550	Band level 850
Chromosome region 1 from p31-p32	1	3	3
Whole chromosome 10	5	12	19
Short arm of chromosome 11	2	5	6
Long arm of chromosome 12	4–5	8	14
Whole chromosome X	6–8	12	18
Total bands counted	18–21	40	60

Table 1.3b Correlation of total bands with band level

Total bands	Band level
18	350
21	400
28	450
34	500
40	550
47	650
54	750
60	850